BIIB
Biogen Inc.

Conference date: February 13, 2024 @ 5:00 AM Pacific Time

Biogen Should Resume Strong Growth with Zuranolone Approval [March 7, 2023 at Seeking Alpha]

Biogen: Beyond The Doom And Gloom [March 7, 2022 at Seeking Alpha]

Biogen's Case for Aduhelm [July 27, 2021 at Seeking Alpha]

Biogen 2021: Two Paths Diverge [February 8, 2021 at Seeking Alpha]

Analyst Conference Summaries available:

2023
Biogen analyst conference summary Q1 2023 Biogen analyst conference summary Q2 2023 Biogen analyst conference summary Q3 2023 Biogen analyst conference summary Q4 2023
April 25, 2023 July 25, 2023 Nov. 8, 2023 Feb. 13, 2024
Q1 2023 Q2 2023 Q3 2023 Q4 2023
2022
Biogen analyst conference summary Q1 2022 Biogen analyst conference summary Q2 2022 Biogen analyst conference summary Q3 2022 Biogen analyst conference summary Q4 2022
May 3, 2022 July 20, 2022 Oct. 25, 2022 Feb. 15, 2023
Q1 2022 Q2 2022 Q3 2022 Q4 2022
2021
Biogen analyst conference summary Q1 2021 Biogen analyst conference summary Q2 2021 Biogen analyst conference summary Q3 2021 Biogen analyst conference summary Q4 2021
April 22, 2021 July 22, 2021 Oct. 20, 2021 Feb. 3, 2022
Q1 2021 Q2 2021 Q3 2021 Q4 2021
2020
Biogen analyst conference summary Q1 2020 Biogen analyst conference summary Q2 2020 Biogen analyst conference summary Q3 2020 Biogen analyst conference summary Q4 2020
April 22, 2020 July 22, 2020 Oct. 21, 2020 Feb. 3, 2021
Q1 2020 Q2 2020 Q3 2020 Q4 2020
2019
Biogen analyst conference summary Q1 2019 Biogen analyst conference summary Q2 2019 Biogen analyst conference summary Q3 2019 Biogen analyst conference summary Q4 2019
April 24, 2019 July 23, 2019 October 22, 2019 January 30, 2020
Q1 2019 Q2 2019 Q3 2019 Q4 2019
2018
Biogen analyst conference summary Q1 2018
Biogen analyst conference summary Q2 2018
Biogen analyst conference summary Q3 2018
Biogen analyst conference summary Q4 2018
April 24, 2018
July 24, 2018
October 23, 2018
January 29, 2019
Q1 2018
Q2 2018
Q3 2018
Q4 2018
2017
Biogen analyst conference summary Q1 2017
Biogen analyst conference summary Q2 2017
Biogen analyst conference summary Q3 2017
Biogen analyst conference summary Q4 2017
April 25, 2017
 July 25, 2017
October 24, 2017
January 25, 2018
Q1 2017
Q2 2017
Q3 2017
Q4 2018
2016
Biogen analyst conference summary Q1 2016
Biogen analyst conference summary Q2 2016
Biogen analyst conference summary Q3 2016
Biogen analyst conference summary Q4 2016
04/21/2016
07/21/2016
10/26/2016
01/26/2017
Q1 2016
Q2 2016
Q3 2016
Q4 2016
2015
Biogen-Idec analyst conference summary Q1 2015
Biogen-Idec analyst conference summary Q2 2015
Biogen analyst conference summary Q3 2015
Biogen analyst conference summary Q4 2015
04/24/2015
07/30/2015
10/21/2015
 01/27/2016
Q1 2015
Q2 2015
Q3 2015
Q4 2015
2014
Biogen-Idec analyst conference summary Q1 2014
Biogen-Idec analyst conference summary Q2 2014
Biogen-Idec analyst conference summary Q3 2014
Biogen-Idec analyst conference summary Q4 2014
04/23/2014
07/23/2014
10/22/2014
01/28/2015
Q1
Q2
Q3
Q4
2013
Biogen-Idec analyst conference summary Q1 2013
Biogen-Idec analyst conference summary Q2 2013
Biogen-Idec analyst conference summary Q3 2013
Biogen-Idec analyst conference summary Q4 2013
04/25/2013
07/25/2013
10/28/2013
01/29/2014
Q1
Q2 
Q3
Q4
2012
Biogen-Idec analyst conference summary Q1 2012
Biogen-Idec analyst conference summary Q2 2012
Biogen-Idec analyst conference summary Q3 2012
Biogen-Idec analyst conference summary Q4 2012
05/01/2012
07/24/2012
10/25/2012
01/28/2013
Q1
Q2 
Q3
Q4
2011
Biogen-Idec analyst conference summary Q1 2011
Biogen-Idec analyst conference summary Q2 2011 
Biogen-Idec analyst conference summary Q3 2011
Biogen-Idec analyst conference summary Q4 2011
04/21/2011
07/26/2011 
 10/28/2011
01/31/2012
Q1
Q2
Q3
 Q4
2010
Biogen-Idec analyst conference summary Q1 2010
 Biogen-Idec analyst conference summary Q2 2010
 Biogen-Idec analyst conference summary Q3 2010
Biogen-Idec analyst conference summary Q4 2010
04/20/2010
 07/20/2010
 10/26/2010
 02/01/2011
Q1
Q2
Q3
Q4
2009
 Biogen-Idec analyst conference summary q1 2009
Biogen-Idec analyst conference summary Q2 2009
 Biogen-Idec analyst conference summary Q3 2009
Biogen-Idec analyst conference summary Q4 2009
04/16/2009
07/16/2009
10/20/2009
02/09/2010
Q1
Q2
Q3
Q4
2008
BIIB analyst conference summary Q1 2008
BIIB analyst conference summary Q2 2008
BIIB analyst conference summary Q3 2008 Biogen Idec
Biogen analyst conference summary Q4 2008
04/23/2008
07/22/2008
10/21/2008
02/06/2009
Q1
Q2
Q3
Q4
2007
BIIB Q4 2007 analyst conference summary
BIIB Q3 2007 conference summary
biib Q2 2007
BIIB summary
02/06/2008
10/23/2007
07/24/2007
05/02/2007
Q4
Q3
Q2
Q1
2006
02/15/2007
10/31/2006
07/26/2006
04/26/2006
Q4
Q3
Q2
Q1

Biogen Aducanumab Committee Danger and Opportunity [October 28, 2020 @ Seeking Alpha]

Biogen's Alzheimer's Therapy Submission In View [April 4, 2020 @ Seeking Alpha]

Biogen Is A Buy Regardless Of Aducanumab [November 6, 2019 @ Seeking Alpha]

Biogen Q2 Results Show Resilience [July 31, 2019 at Seeking Alpha]

Biogen 2019 Outlook [February 11, 2019 at Seeking Alpha]

Biogen Outlook For The 2020s November 30, 2018

Biogen's Ionis Deal is Brilliant [April 25, 2018 at Seeking Alpha]

Biogen's Key Variable: Its Neuroscience Pipeline [March 18, 2018 at Seeking Alpha]

Biogen Key Q1 2017 Insights [April 26, 2017 @ Seeking Alpha]

Bioverativ Should Have A Strong Launch [Jan. 10, 2017 @ Seeking Alpha]

Biogen Spinraza (nusinersen) positive interim analysis of Phase 3 later-onset Spinal Muscular Atrophy trial [Biogen 11/7/16 press release]

Biogen Keys to Value in 2017 and Beyond [June 2, 2016 at Seeking Alpha]

A Look At Biogen's 2016 Catalysts [January 12, 2016 at Seeking Alpha]

Biogen Intends to Spin-off Hemophilia Business [5/4/2016 Biogen press release]

Can Biogen Idec Take Wing With Tecfidera? [July 29, 2014]
Biogen Idec: Too High Too Fast? [April 29, 2013]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Biogen Idec: Q3 Clues to Value [November 2, 2011]
Biogen Idec: Is there More Value? [July 11, 2011]
Biogen Idec PML Test Approved in Europe, Changing Tysabri Outlook [March 15, 2011]
Biogen Idec Hemophilia Therapies [September 30, 2010]
Gilenya, Biogen Idec, and MS [September 22, 2010]
FDA February 5, 2010 Tysabri and PML letter
Biogen Research and Development Presentation notes [March 25, 2009]
Biogen Idec Growth Acceleration [October 27, 2008 blog]
Biogen Idec: Will it Recover? [September 1, 2008 blog]
Choosing a Biotech Stock 3: Biogen Idec [September 14, 2007 blog]
Rituxan and Zevalin, A Cautionary Tale [July 14, 2007 at New York Times, registration required]
Biogen Idec and Tysabri [May 6, 2007 blog]

First acquired in February 2008

Biogen is a biotechnology pharmaceutical company which markets Tecfidera, Spinraza, Avonex, Tysabri, aduhelm and other drugs.

Biogen Web site:

Biogen main page

Biogen investor page

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2024 William P. Meyers